All News

Found 543 articles

• CytomX Therapeutics, Inc. Appoints Immuno-Oncology Leader Rachel Humphrey, M.D., To Board Of Directors

  3/19/2015

• Mirati Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Business Update

  3/11/2015

• Assembly Biosciences Announces Senior Management Changes

  2/17/2015

• Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

  2/4/2015

• Mirati Therapeutics To Present At The Leerink Global Healthcare Conference

  1/30/2015

• Mirati Therapeutics To Present At The Leerink Global Healthcare Conference

  1/30/2015

• Mirati Therapeutics Announces Proposed Public Offering Of Common Stock

  1/29/2015

• Mirati Therapeutics Announces Proposed Public Offering Of Common Stock

  1/28/2015

• Mirati Therapeutics Doses First Patient In Phase 2 Study Of Mocetinostat In Bladder Cancer Patients With Genetic Alterations Of CREBBP And EP300

  1/7/2015

• Mirati Therapeutics Doses First Patient In Investigator-Sponsored Phase 2 Study Of Mocetinostat In Non-Hodgkin's Lymphoma

  1/6/2015

• Mirati Therapeutics Doses First Patient In Expansion Cohorts Of Phase 1b Trial Of MGCD265 In Genetically Selected Patients

  12/23/2014

• Ziarco Announces Appointment Of Mike Grey To Board Of Directors

  12/4/2014

• Mirati Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference

  11/19/2014

• Mirati Therapeutics Reports Third Quarter 2014 Financial Results And Provides Business Update

  11/10/2014

• Michael Grey Joins Mirati Therapeutics Board Of Directors

  11/6/2014

• Five Prime Therapeutics, Inc. Appoints Bill Ringo To Its Board Of Directors

  10/3/2014

• Mirati Therapeutics To Present At BioCentury's NewsMakers In The Biotech Industry Conference

  9/10/2014

• Mirati Therapeutics Initiates Phase 1 Study Of MGCD516 For Non-Small Cell Lung Cancer And Other Advanced Solid Tumors

  9/4/2014

• Mirati Therapeutics Receives Orphan Designation From U.S. FDA For Mocetinostat In Diffuse Large B-Cell Lymphoma

  8/11/2014

• Mirati Therapeutics Reports Second Quarter 2014 Financial Results And Provides Business Update

  8/8/2014